Berakhot
Posted - 1 day ago
$DTIL "These in vivo gene editing programs r designed to take advantage of unique attributes of ARCUS, namely: cut, size, and simplicity. Next steps will prepare for GLP toxicology studies followed by potential IND & clinical trial application (CTA) submissions,” said Jeff Smith, Co-Founder & CRO. “We r excited about compelling in vivo proof-of-concept data generated for ARCUS gene excision of “hot spot” region of dystrophin gene in DMD program. Additionally, in vivo data for gene insertion program demonstrated up to 45% high efficiency gene insertion in non-dividing cells of non-human primates measured by total liver tissue. This is important & differentiating proof-of-concept data for ARCUS compared to CRISPR, base editors & prime editors, which have not demonstrated high levels of gene insertion efficiency in dividing or non-dividing cells in vivo, potentially enabling broader therapeutic applicability for ARCUS." https://www.businesswire.com/news/home/20240416117356/en/Precision-BioSciences-Announces-Return-of-Programs-and-Conclusion-of-Collaboration-with-Prevail-Therapeutics
dbender603
Posted - 3 days ago
$BLUE interesting that $DTIL was given their project back by lily they have $verb that had to halt their project wouldn’t it be interesting if they went after one that was already approved and starting to gain traction? Me thinks this could spell blue sky’s ahead!
LabPsycho
Posted - 3 days ago
$DTIL @DangRanger The writing was on the wall was it 2 or 3 yr ago now with their massive InstaDilution(TM) on the slightest good news. That should have shown you then the management of this company seemingly cares nothing about existing shareholders - as I pointed out years ago. ditto for PSTX and myriad other self-serving companies that dilute on the way down.
DangRanger
Posted - 3 days ago
$DTIL nightmare scenario. recerse aplit and tank back to pennies incoming. need miracle news.
HypnoTrader
Posted - 4 days ago
$DTIL When they did an offering a little while ago, everyone was wondering why. Didn't they have a partnership and plenty of cash? Some suggested it was to save the company from evil foreign Tang fund. Well, now we know why. Management had to act fast. Illi was walking away. A lot was at stake here. Salaries, bonuses, private school tuitions, yachts and vacations. Thankfully, managers were able to sell shares to the market before retail investors found out. It was a close call, but all is well that ends well. The luxurious lifestyle was saved and no one who matters got hurt. NRPI.
Chipoo
Posted - 4 days ago
$DTIL The share price and what it will become until the next catalyst is concerning. OTC data might not be until early 2025.
valueforme
Posted - 5 days ago
$DTIL Lilly needs speed. Arcus nucleases generation is slooooooow. Lilly moves on by doubling down on RNA editing imho
OpenOutcrier
Posted - 5 days ago
$DTIL (-11.0% pre) Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics - SI https://ooc.bz/l/30563
Pharmsci01
Posted - 6 days ago
$DTIL Their CART was made by their gene editing technology, that means this method is working in vitro. But, in vivo results need to be proved by phase 1 efficacy data. Let's see what iCURE's first on human come out.
GuyFawkes_EOD
Posted - 6 days ago
$DTIL was nicely green on this one just a month back 🤦♂️
Ebrice73
Posted - 6 days ago
$DTIL ok …well what does this mean for other gene editing companies?…
enyce1995
Posted - 6 days ago
$DTIL Something tells me the BOD knew this was happening and approved the secondary. If that's the case, they are done.
Hydrogem
Posted - 6 days ago
$DTIL Sorry to whoever is still here. I left long ago but, but still painful nonetheless. Turn out the lights, it’s over.
DonCorleone77
Posted - 6 days ago
$DTIL $LLY Precision announces return of programs, conclusion of collab with Prevail Precision BioSciences (DTIL) announced the anticipated return of three programs from Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company (LLY). Precision exercised its option to regain rights for the programs following Prevail Therapeutics' decision to conclude the collaboration. Precision uses its novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision. "We enjoyed a productive gene editing collaboration with Prevail Therapeutics and appreciate their contributions to the success of these programs. Together, we advanced three programs from concept toward clinical candidates, and Precision completed its workplan for these programs to the next stage gate, taking us to an important development decision point," said Michael Amoroso, President and Chief Executive Officer of Precision BioSciences. "Our decision to regain control of the programs brings exciting development opportunities to Precision's pipeline with a focus on benefiting people born with incurable genetic diseases."
Stock_Titan
Posted - 6 days ago
$DTIL Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
https://www.stocktitan.net/news/DTIL/precision-bio-sciences-announces-return-of-programs-and-conclusion-n4b4bof07n7j.html
Ebrice73
Posted - 1 week ago
$DTIL so rigged! Hold on… this is going to fly
PeterDinklage
Posted - 1 week ago
$DTIL thank you pre market
PeterDinklage
Posted - 1 week ago
$DTIL maybe DTIL will be apart of the cure for whatever they sprayed over the eclipse path? Pandemic 2.0 ?
steven1x
Posted - 2 weeks ago
$DTIL what’s the near term catalyst for Tgtx agreement ?
Upon the achievement of certain near-term clinical milestones, Precision will receive an additional $7.5 million payment in cash and the purchase of Precision common stock by TG Therapeutics at a 100% premium to the then current 30-day VWAP. Precision is eligible to receive up to $288 million in additional milestone payments based on the achievement of certain clinical, regulatory, and commercial milestones, in addition to high-single-digit to low-double-digit royalties on net sales.
PeterDinklage
Posted - 2 weeks ago
$DTIL 9$ please.
commoncentsinvestor
Posted - 2 weeks ago
$DTIL SHOULD BE BIG WINNER Anyone looking for a stock that could have a big increase in share price in 2024 might want to take a look at CVRX. They got FDA approval for its Barostim product to improve the lives of people suffering from heart failure back in 2019. They have spent the last 4 years building a market for their product and it is about to reap big rewards. They have been increasing their revenues, the number of implant centers, their territories, , and their public visibility by leaps and bounds and work on 84% gross margins. This should all result in big increases in revenues and share price this year. I expect a minimum of $65M in 2024 revenues and with 84% Gross Margins, a 15 times Market Cap would be very reasonable. That would put the share price at about $47. Current Share Price is under $18. With only 600 followers on Stock Twits, it is very early in the game for folks who like to invest in under followed small companies with HUGE potential.
ManfredMustermann
Posted - 2 weeks ago
$DTIL what catalyst next ahead?
PeterDinklage
Posted - 2 weeks ago
$DTIL pretty please
steven1x
Posted - 2 weeks ago
$DTIL what’s the money tied this IND clearance?
With this IND clearance, we are now activating sites in three countries in distinct geographical areas – United States, United Kingdom and Australia – which will facilitate families’ ability to access this landmark clinical trial,” said Joe Truitt, Chief Executive Officer of iECURE. “We are working diligently to open sites so we can start enrolling patients for dosing. The trial will be accepting eligible baby boys with neonatal onset OTC deficiency from all over the world, and we hope to see positive safety data and indications of efficacy with this trial.”
Stock_Titan
Posted - 2 weeks ago
$DTIL iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the U.S.
https://www.stocktitan.net/news/DTIL/i-ecure-announces-fda-clearance-of-investigational-new-drug-1wohhr0gok0p.html
hey_jakey
Posted - 2 weeks ago
FDA clears iECURE IND application for OTC using $DTIL ARCUS. Phase 1/2 FIH trials now in US, UK, and Australia. Great news the US is on-board now too. Just the start for ARCUS.
Tshanky_
Posted - 2 weeks ago
$DTIL cruising